Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
- PMID: 37123234
- PMCID: PMC10130924
- DOI: 10.1016/j.isci.2023.106561
Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
Erratum in
-
Erratum: Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice.iScience. 2023 Aug 31;26(9):107724. doi: 10.1016/j.isci.2023.107724. eCollection 2023 Sep 15. iScience. 2023. PMID: 37694153 Free PMC article.
Abstract
Aquaporin-8(AQP8), is a transmembrane channel protein that abounds in liver, which mainly promotes water transport, modulating bile acid formation. However, its role in hepatic lipid metabolism remains unclear. In this study, we found the expression of AQP8 was reduced in liver specimens of patients with NAFLD, high-fat diet (HFD)-induced mice and genetically obese db/db mice. Knockdown of AQP8 in hepatocytes exacerbated the intracellular lipid accumulation induced by free fatty acid (FFA) mixtures. In contrast, hepatic AQP8 overexpression activated farnesoid X receptor (FXR), inhibiting gene expression associated with lipogenesis, which further reduced intrahepatic triglyceride overload in obese mice. FXR knockout abrogated the ameliorating effect of AQP8 overexpression on NAFLD in mice. These findings indicate that AQP8 overexpression protects against fatty liver through activating the FXR pathway.
Keywords: Cell biology; Endocrinology; Molecular biology.
© 2023 The Authors.
Conflict of interest statement
The authors declare no competing interests.
Figures








References
-
- Cotter T.G., Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–1864. - PubMed
-
- Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013;10:330–344. - PubMed
-
- Aron-Wisnewsky J., Vigliotti C., Witjes J., Le P., Holleboom A.G., Verheij J., Nieuwdorp M., Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 2020;17:279–297. - PubMed
-
- Powell E.E., Wong V.W.S., Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–2224. - PubMed
-
- Sheka A.C., Adeyi O., Thompson J., Hameed B., Crawford P.A., Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175–1183. - PubMed
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous